1131676
Last Update Posted: 2016-05-16
Recruiting has ended
All Genders accepted | 18 Years + |
7064 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).
The aim of the present study is to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.
Eligibility
Relevant conditions:
Diabetes Mellitus, Type 2
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov